

Francesco Gelsomino

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6799768/francesco-gelsomino-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

161
papers

5,093
citations

32
h-index

68
g-index

174
ext. papers

7,087
ext. citations

5.5
avg, IF

5.69
L-index

#	Paper	IF	Citations
161	Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.. <i>Targeted Oncology</i> , 2022 , 17, 43-51	5	1
160	Monitoring tumor growth rate to predict immune checkpoint inhibitors treatment outcome in advanced NSCLC.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359211058391	5.4	
159	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103561	7	3
158	Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation. <i>Clinical Lung Cancer</i> , 2021 ,	4.9	0
157	Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients. <i>Tumori</i> , 2021 , 3008916211000808	1.7	1
156	Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. <i>Anti-Cancer Drugs</i> , 2021 , 32, 758-762	2.4	2
155	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83	7.5	8
154	Overexpression of microRNA-486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting. <i>International Journal of Molecular Medicine</i> , 2021 , 47,	4.4	1
153	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression $\geq 50\%$: Selecting the best strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103302	7	6
152	Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021 , 11, 642190	5.3	10
151	A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3135-3137	4.9	
150	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) 2021 , 9,		3
149	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre 'real-world' study. <i>European Journal of Cancer</i> , 2021 , 148, 24-35	7.5	8
148	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021 , 150, 224-231	7.5	8
147	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 666156	5.7	1
146	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2917-2936	4.4	5
145	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2890-2916	4.4	6

144	Pneumothorax and pulmonary hemorrhage after CT-guided lung biopsy: incidence, clinical significance and correlation. <i>Radiologia Medica</i> , 2021 , 126, 170-177	6.5	5
143	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021 , 142, 18-28	7.5	27
142	IFN- γ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021 , 13,	6.6	7
141	Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. <i>Biochemical Pharmacology</i> , 2021 , 190, 114643	6	3
140	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
139	Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report. <i>Investigational New Drugs</i> , 2021 , 1	4.3	2
138	Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. <i>European Journal of Cancer</i> , 2021 , 157, 520-522	7.5	
137	Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. <i>Clinical Lung Cancer</i> , 2021 , 22, 473-477	4.9	3
136	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100214	1.4	1
135	Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 166, 103454	7	5
134	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1438-1447	21.7	18
133	STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?. <i>European Journal of Cancer</i> , 2021 , 157, 108-113	7.5	4
132	Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database. <i>Lung Cancer</i> , 2021 , 161, 18-25	5.9	1
131	A sulfonyl fluoride derivative inhibits EGFR by covalent modification of the catalytic lysine. <i>European Journal of Medicinal Chemistry</i> , 2021 , 225, 113786	6.8	4
130	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 \geq 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.. <i>Thoracic Cancer</i> , 2021 ,	3.2	2
129	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920954802	5.4	3
128	Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. <i>Thoracic Cancer</i> , 2020 , 11, 1661-1669	3.2	1
127	Cystic brain metastases and fusion in lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 424-425	4.4	0

126	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , 2020 , 21, 914-922	21.7	328
125	The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020 , 43, 196-203	5	16
124	Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00570	3.1	
123	Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer. <i>Data in Brief</i> , 2020 , 31, 105781	1.2	0
122	A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?. <i>Anti-Cancer Drugs</i> , 2020 , 31, 211-215	2.4	3
121	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
120	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020 , 130, 155-167	7.5	53
119	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020 , 128, 17-26	7.5	41
118	Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer. <i>Immunotherapy</i> , 2020 , 12, 183-193	3.8	4
117	Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). <i>British Journal of Cancer</i> , 2020 , 123, 26-32	8.7	7
116	Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. <i>Clinical Lung Cancer</i> , 2020 , 21, e464-e473	4.9	12
115	Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 , 58, 619-628	3	5
114	Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC. <i>Lung Cancer</i> , 2020 , 144, 30-39	5.9	9
113	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	
112	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. <i>Cancers</i> , 2020 , 13,	6.6	3
111	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1047-1059	5.4	3
110	Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102820	7	25
109	Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020 , 382, 41-50	59.2	771

108	Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2020 , 21, e65-e73	4.9	2
107	Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 2020 , 8,		0
106	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11
105	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 156, 103119	7	31
104	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
103	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920952994	5.4	9
102	Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920915983	5.4	2
101	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020 , 15, 449-466	5	37
100	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020 , 150, 123-131	5.9	4
99	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. <i>Cancers</i> , 2020 , 12,	6.6	15
98	Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020 , 12,	6.6	21
97	Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy. <i>Immunotherapy</i> , 2020 , 12, 1139-1148	3.8	6
96	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920913801	5.4	5
95	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020 , 22, 41	6.3	10
94	Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 7312-7319	12.9	80
93	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101887	14.4	25
92	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. <i>Targeted Oncology</i> , 2019 , 14, 619-626	5	15
91	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. <i>Cancers</i> , 2019 , 11,	6.6	4

90	Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019 , 121, 725-737	8.7	295
89	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019 , 46, 100644	23.2	67
88	Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 141-143	8.9	1
87	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 222	12.8	22
86	Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 461-471	3.5	7
85	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019 , 166, 128-138	6	9
84	Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine. <i>Future Oncology</i> , 2019 , 15, 1125-1134	3.6	5
83	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. <i>Lung Cancer</i> , 2019 , 131, 78-85	5.9	28
82	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2019 , 9, 179	5.3	23
81	BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e57-e59	8.9	13
80	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. <i>Lung Cancer</i> , 2019 , 134, 210-217	5.9	8
79	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019 , 123, 72-80	7.5	34
78	Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?. <i>JCO Precision Oncology</i> , 2019 , 3, 1-2	3.6	
77	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 2019 , 7, 316		56
76	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919885540	5.4	12
75	The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. <i>Molecules</i> , 2019 , 24,	4.8	2
74	The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. <i>Lung Cancer</i> , 2019 , 127, 153-163	5.9	42
73	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , 2019 , 120, 57-62	8.7	40

72	Immune-mediated cholangitis: is it always nivolumab® fault?. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 1325-1327	7.4	4
71	Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?. <i>Annals of Oncology</i> , 2018 , 29, 284-286	10.3	12
70	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. <i>Cancer Treatment Reviews</i> , 2018 , 66, 82-94	14.4	66
69	Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e89-e91	8.9	22
68	A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. <i>Investigational New Drugs</i> , 2018 , 36, 144-146	4.3	30
67	Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. <i>Clinical Cancer Research</i> , 2018 , 24, 407-419	12.9	124
66	Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. <i>Immunotherapy</i> , 2018 , 10, 681-694	3.8	25
65	Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e247-e248	8.9	0
64	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 2857-2873	4.4	7
63	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2027-2039	59.2	427
62	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. <i>Lung Cancer</i> , 2018 , 126, 9-14	5.9	23
61	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
60	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1281-1287	2.2	84
59	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , 2017 , 111, 30-37	5.9	20
58	P3.02c-094 Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336	8.9	5
57	P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1336-S1337	8.9	2
56	Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. <i>Annals of Oncology</i> , 2017 , 28, 671-672	10.3	59
55	Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017 , 8, 45-55	2.9	22

54	Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 174	12.8	36
53	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 353-373	4.9	19
52	Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder. <i>Tumori</i> , 2017 , 103, 66-71	1.7	4
51	Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review. <i>Tumori</i> , 2017 , 103, e12-e15	1.7	0
50	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. <i>Oncotarget</i> , 2017 , 8, 91841-91859	3.3	20
49	Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need?. <i>Translational Cancer Research</i> , 2017 , 6, S1484-S1488	0.3	3
48	Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?. <i>Current Drug Targets</i> , 2017 , 18, 13-26	3	13
47	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. <i>Lung Cancer</i> , 2016 , 100, 30-37	5.9	3
46	L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e121-3	8.9	110
45	K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. <i>Lung Cancer</i> , 2016 , 93, 55-8	5.9	29
44	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , 2016 , 8, E403-7	2.6	1
43	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016 , 5, 301-21	4.4	33
42	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 681-96	3.5	6
41	Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e99-e101	8.9	3
40	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 213-27	7	42
39	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2015 , 30, 429-30	3	1
38	FGFR as potential target in the treatment of squamous non small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015 , 41, 527-39	14.4	46
37	Classification of different patterns of pulmonary adenocarcinomas. <i>Expert Review of Respiratory Medicine</i> , 2015 , 9, 571-86	3.8	17

36	Paradoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome. <i>Journal of Clinical Virology</i> , 2015 , 62, 54-7	14.5	9
35	Second-line Treatment of Small Cell Lung Cancer: Is Platinum Sensitivity a Relevant Prognostic Factor?. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e35-e36	8.9	
34	ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. <i>Diagnostic Cytopathology</i> , 2015 , 43, 941-6	1.4	36
33	Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. <i>PLoS ONE</i> , 2015 , 10, e0142891	3.7	9
32	Curved Needles in CT-Guided Fine Needle Biopsies of Abdominal and Retroperitoneal Small Lesions. <i>CardioVascular and Interventional Radiology</i> , 2015 , 38, 1611-6	2.7	16
31	Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014 , 83, 265-71	5.9	33
30	Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. <i>European Journal of Cancer</i> , 2014 , 50, 2211-8	7.5	32
29	Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 859-63	2.2	2
28	Targeting the MET gene for the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 284-99	7	61
27	First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?. <i>Journal of Thoracic Oncology</i> , 2014 , 9, e82	8.9	4
26	MET and Small-Cell Lung Cancer. <i>Cancers</i> , 2014 , 6, 2100-15	6.6	26
25	Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients. <i>Lung Cancer</i> , 2014 , 86, 324-8	5.9	24
24	Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. <i>Translational Lung Cancer Research</i> , 2014 , 3, 173-80	4.4	13
23	MET and ALK as targets for the treatment of NSCLC. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3914-32	3.3	3
22	Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. <i>Diagnostic Cytopathology</i> , 2013 , 41, 595-8	1.4	20
21	Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. <i>Radiologia Medica</i> , 2013 , 118, 1071-81	6.5	39
20	Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 80, 35-8	5.9	11
19	Fishing for ALK with immunohistochemistry may predict response to crizotinib. <i>Tumori</i> , 2013 , 99, e229-e232	3.2	5

18	Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3291-3296	3.2	14
17	Asymptomatic Pulmonary Embolism in Lung Cancer: Prevalence and Analysis of Clinical and Radiological Characteristics in 141 Outpatients. <i>Tumori</i> , 2012 , 98, 594-600	1.7	12
16	Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. <i>Tumori</i> , 2012 , 98, 594-600	1.7	6
15	EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. <i>Lung Cancer</i> , 2011 , 71, 241-3	5.9	97
14	Endometrial metastasis of lung adenocarcinoma: A case report. <i>Tumori</i> , 2011 , 97, 411-414	1.7	12
13	Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 489-93	8.9	74
12	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2011 , 6, 181-6	5	7
11	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1677-87	3.5	23
10	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1631-40	3.5	16
9	Endometrial metastasis of lung adenocarcinoma: a case report. <i>Tumori</i> , 2011 , 97, 411-4	1.7	9
8	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). <i>Drug Design, Development and Therapy</i> , 2010 , 4, 81-98	4.4	34
7	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. <i>Lung Cancer</i> , 2010 , 67, 355-60	5.9	59
6	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 425-35	3.5	23
5	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , 2009 , 64, 199-206	5.9	19
4	Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report. <i>Lung Cancer</i> , 2009 , 65, 251-3	5.9	7
3	Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1104-11	8.9	29
2	Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma. <i>Tumori</i> , 2007 , 93, 138-144	1.7	50
1	Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 847-57	9.7	496

